The Orange Book explained

FDA proposed the list in the Federal Register on Jan. 12, 1979¹, finalized the rule on Oct. 31, 1980, and printed the first edition that same month. Its formal title, Approved Drug Products with Therapeutic Equivalence Evaluations, never caught on. People called it the Orange Book after the color of its cover, and the name stuck through the move from paper to a searchable website.

Forty-six years later the book has become the reference that every generic drug passes through. GxRadar's count of FDA's Drugs@FDA records⁸ shows 19,593 original generic applications approved from 1984 through Oct. 27, 2026, and each approved product is listed there with a code that tells pharmacists whether it can stand in for the brand (see our approvals tracker).

It does three jobs at once. It is FDA's official list of approved drug products. It records the patents and exclusivities that can hold generic competition back. And it carries the therapeutic equivalence codes that pharmacists and state substitution laws rely on. Anyone trying to work out when a cheaper version of a drug might arrive, or whether the version in the bottle is interchangeable with the brand, ends up reading it.

From a 1980 rule to a statutory duty

FDA first framed the list as advice to the states. Its equivalence ratings were prepared, in the preface's words, "to serve as public information and advice to state health agencies, prescribers, and pharmacists." Congress then made the list a legal requirement. When the Drug Price Competition and Patent Term Restoration Act was signed on Sept. 24, 1984, it required FDA to publish a list of approved drug products with monthly supplements, according to the Orange Book's preface¹. That law, better known as Hatch-Waxman, also created the modern generic approval pathway, which is why patents and exclusivity periods ended up recorded alongside the product listings.

FDA organizes the book into four product lists: prescription drugs, over-the-counter drugs, drugs approved under section 505 of the Food, Drug, and Cosmetic Act that are administered by FDA's biologics center, and discontinued products. A separate Patent and Exclusivity Information Addendum holds the patent and exclusivity data. Over-the-counter products are listed but not rated for equivalence, and discontinued products carry no equivalence code¹. Most biologics are licensed under a different law and sit in a separate FDA database, the Purple Book, a split our piece on biosimilars and generics explains.

A database that changes daily

The paper edition is gone. The annual edition is now a PDF, and most users go straight to the electronic Orange Book search, linked from FDA's Orange Book page⁹. Since February 2005, FDA has added new generic approvals to the electronic version daily, the agency's Orange Book FAQ says². Before that, a first generic approved early in a month could wait several weeks to appear.

Everything else moves on a monthly cycle. The cumulative supplement, which collects the prior month's changes, generally posts at the end of the second week of each month. FDA also publishes downloadable data files³ for products, patents and exclusivities on the same schedule, which is what researchers and payers use to track when competition is likely for a given drug.

How to read a product entry

Products are grouped by active ingredient, then by dosage form and route. Within each group FDA usually flags one product per strength as the reference listed drug (RLD), typically the original brand. Generics rated against it carry a therapeutic equivalence code. The data files use these fields:

FDA's own suggestion for a lookup is to search by trade name to find the active ingredient, then search by ingredient to see every approved version. A code only means something when products share the same ingredient, dosage form, route and strength. An AB rating on a 10 mg tablet says nothing about a 20 mg capsule.

A rating is a scientific call and nothing more. The preface says¹ equivalence evaluations do not mean any product is preferable to another, and that generic substitution "may involve social and economic policy administered by the states." FDA rates; states decide what a pharmacist may swap.

The patent section, filled in by the brand

FDA does not choose which patents appear. The brand's application holder does, and FDA's role is largely ministerial. Under 21 CFR 314.53⁴, three kinds of patents must be submitted if an infringement claim could reasonably be asserted against an unlicensed generic: drug substance patents covering the active ingredient, drug product patents covering the formulation, and method-of-use patents covering an approved use. Patents on manufacturing processes, packaging, metabolites and intermediates may not be submitted.

Deadlines are tight. Qualifying patents go to FDA on Form FDA 3542 within 30 days of approval, or within 30 days of a new patent issuing, and the regulation says FDA will not list patent information that arrives any other way.

Each patent row shows the number, the expiration date including any extension, flags for drug substance and drug product claims, and a use code for method-of-use patents. The use code is a short description of the patented use, which a generic applicant compares with its own proposed labeling when it decides how to certify. When pediatric exclusivity applies, the patent appears twice, once with its original expiration and once with six months added, FDA's patent and exclusivity FAQ explains⁵.

A delist request flag marks a patent the brand has asked to remove that stays listed anyway, because a first generic filer may still be entitled to 180-day exclusivity based on it. That flag is defined in FDA's data file documentation³. The certifications behind it, including the Paragraph IV challenges that trigger patent lawsuits, are described on FDA's patent certification page⁷.

Exclusivity codes

Exclusivities are granted by FDA rather than the patent office, and each appears with a code and an expiration date. Common ones include NCE (new chemical entity, five years), ODE (orphan drug, seven years), PED (pediatric, six months) and PC, the 180-day exclusivity earned by a first generic filer that successfully challenges a patent. Pediatric exclusivity does not stand alone; it attaches six months to existing patents and exclusivities, FDA's FAQ notes⁵. Expired patents and exclusivities drop off the listing.

What the 2021 transparency law changed

Congress tightened the rules with the Orange Book Transparency Act of 2020⁶, which became law on Jan. 5, 2021. It wrote the three listable patent categories into the statute itself and required exclusivity periods to be listed once FDA determines their expiration dates.

It also dealt with patents that no longer hold up. When the Patent Trial and Appeal Board or a court issues a final decision cancelling or invalidating a listed claim, the brand must notify FDA within 14 days, and FDA amends or removes the listing. One exception applies. FDA cannot pull a patent this way while a first generic filer could still claim 180-day exclusivity based on it. The act also directed the Government Accountability Office to study patents that claim a drug together with a delivery device, such as an inhaler.

Patient questions about which listed version is in a given bottle are best taken to a pharmacist, who can match the product to its entry. For the rest of the life of a generic after it is listed, including price changes and shortages, the GxRadar drug pages pull the federal data into one place.